Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Allergan will establish an R&D presence in the Kendall Square section of Cambridge, Massachusetts, a hub of science, innovation and business opportunities. The site will be led by Don Frail, PhD, Senior Vice President of Research and External Scientific Innovation (RESI) and Non-Clinical and Translational Sciences.

Allergan to establish R&D presence in Cambridge, Massachusetts

"One of the driving sources of innovation today comes from smaller biotechnology and pharma companies. Our new, strategic presence in Kendall Square will allow us to more easily interact and engage with venture firms and start ups in the area," said David Nicholson, EVP & Chief R&D Officer. "I am confident that our new location in Cambridge, along with Don's deep expertise will accelerate the evaluation of scientific opportunities and further deliver on our Open Science model and the next wave of potentially transformational medicines."

Dr Frail joined Allergan in 2014, relocating from Boston to the Allergan R&D center in Irvine, CA, and has led the Research, Clinical Pharmacology, Toxicology and ADME departments including the External Science & Innovation initiatives to evaluate and implement partnerships and acquisitions across Allergan's four key therapeutic areas. Don will continue to lead the Irvine team as well. Previously, Frail led the Emerging Innovations Unit at AstraZeneca, the Indications Discovery Units at Pfizer and the CNS Discovery organization at Pharmacia.

"I'm looking forward to returning to the Boston area to establish Allergan's new presence where we will continue to identify cutting-edge technologies and opportunities that deliver the highest value to patients and their healthcare providers. Our Irvine site will continue to be the home of R&D and retain its long-established External Scientific Innovation and Non-Clinical Translational Sciences team. The new Cambridge group will be fully integrated with the Allergan organization, and serve as a portal to our other R&D sites in Madison NJ, San Francisco area, and globally," said Don Frail.

Read More

Related news

Changes needed to prevent controversial pay-for-delay pharma deals

Changes needed to prevent controversial pay-for-delay pharma deals

26 May 2020

Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

Read more 
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

26 May 2020

SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

Read more 
AbCellera and Lilly seal multi-year antibody discovery collaboration

AbCellera and Lilly seal multi-year antibody discovery collaboration

25 May 2020

AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.

Read more 
HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

25 May 2020

The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more